http://www.medicaldiagnostics.com.au
Medical Diagnostics Australasia (MDA) was formed in September 1997 primarily to fulfil the increasing demand for the HUT rapid urease test and the Urea Breath Test for Helicobacter pylori infection diagnosis, which were previously supplied by the Gastrointestinal Sciences Research Group, based at Mornington Peninsula Hospital, Frankston. Over the years the staff at MDA have also been involved in several research projects and clinical treatment trials. The productive research that staff members have been involved in both prior to and since MDA was formed has resulted in numerous publications regarding the diagnosis and treatment of Helicobacter pylori infection. We have also recently introduced a new range of self - testing kits which are available to members of the general public for use in the privacy of their own home. In addition to continuing to provide the HUT rapid urease test and urea breath testing services, Medical Diagnostics Australasia offers clinical advice as to the interpretation of these tests and the management of patients infected with H.pylori by a consultant Gastroenterologist. We have expanded our product lines by providing selected instrumentation and a wider range of diagnostic tests which are most suitable for pathology laboratories. Our aim is to provide the highest standard of tests for the diagnosis of human diseases.
Medical Diagnostics and Consulting is dedicated to providing cardiac and respiratory diagnostic testing to the residents of Northwestern Ontario. By providing quick access to tests at various locations within the city of Thunder Bay, we act as a resource for physicians in the diagnosis and management of their patients with cardiac and respiratory problems.
http://www.polychromemedical.com
PolyChrome Medical was founded in 1995. We manufacture and have worldwide distribution of the CF Indicator Sweat Test System. The System is used in screening for the debilitating genetic disease Cystic Fibrosis. In 1999 we expanded our services to include contract manufacturing and packaging. Our contract services span several different industries including medical, cosmetic, photographic, electronic and industrial applications. We are an FDA registered facility as well as a registered Drug Re-labeler. PolyChrome Medical has a proud history of providing the most accurate, rapid and cost effect qualitative chloride sweat test available in the marketplace. The test is used in screening for cystic fibrosis. It is the number one test used worldwide. The CF Indicator Sweat Test System uses pilocarpine iontophoresis for sweat stimulation. The stimulator was originally designed and engineered by Medtronic. A chloride concentration test patch, developed at the University of Minnesota, is used to collect and analyze the sweat. The system is completely portable and does not require any additional laboratory equipment or processes. Our contract manufacturing/packaging services grew out of the many requests we received for assistance with start up medical projects. As a result, most of our contract services utilize some type of custom manufacturing or packaging equipment. We approach each project with the intention of continually improving the process and throughput. Our goal is to share our savings with our customers.
PanScope specializes in online sales and distribution of high quality medical diagnostic equipment and accessories from the industry's leading manufacturers. Our web site is available for the placement of orders and research 7 days a week, 24 hours a day. You may reach us by telephone at 1-800-734-7715 Monday through Friday 8:00 AM to 5:00 PM EST or via email (support@panscope.com) with any questions you have regarding our products, your order, and returns or exchanges. PanScope specializes in online sales and distribution of high quality medical diagnostic equipment and accessories from the industry's leading manufacturers. Our web site is available for the placement of orders and research 7 days a week, 24 hours a day. You may reach us by telephone at 1-800-734-7715 Monday through Friday 8:00 AM to 5:00 PM EST or via email (support@panscope.com) with any questions you have regarding our products, your order, and returns or exchanges.
Advanced Medical Diagnostics Group is made up of dedicated professionals. The company was founded in February 1999 by Paul Highett-Smith (Chairman) and Dr Malcolm Ellis (Managing Director). It has been entirely funded by the founders and a small group of founding shareholders and debt providers. Our differentiating philosophy is to be driven by products that respond to the needs of patients. This will be achieved initially through the unique VariaCardio® TF5 Advanced Heart Monitor system and subsequently through other products, which can predict and help prevent the risks of failing health. We are focusing our attentions on the screening and diagnoses of failing hearts with the VariaCardio® TF5 Advanced Heart Monitor system. The reasons for this are: , Heart disease is the number 1 cause of death in the world.
International Murex Technologies Corporation (Nasdaq symbol MURXF) is a vertically integrated, medical diagnostic products company, that through its subsidiaries is dedicated to the research, manufacture and marketing of products for the detection, monitoring and screening of infectious diseases and other medical conditions. The Company manufactures and markets on a worldwide basis more than 600 products. Murex has marketing and distribution activities in more than 100 countries with direct local representatives in 35 leading markets.
Biomedical Diagnostic Research, Inc has been serving the medical research community since 2001. Currently, we specialize in diagnostic research involving the monitoring of Anti-Aging, DNA Repair, and successes of medical intervention. The focus of this site is to introduce you to exciting new research being done with regard to DNA repair. You will learn about our services and our professional staff. While browsing this site, you may have comments or questions about our products and services; or if you simply need more information contact us by clicking on the contact button on any page within this site.
FDI Medical is part of the national network of successful independent medical distributors, UniMed, Inc. FDI Medical is uniquely positioned to provide manufacturers with a specialized sales force that can successfully distribute current products as well as launch new products across the United States. FDI Medical proudly represents products that promote a healthy lifestyle, and that aid in the management of chronic disease. Members are highly qualified and run well-established companies in their respective local and/or regional markets. The alliance of these companies brings together a vast amount of industry knowledge and experience to provide superior customer support, training and education, equipment service, and field sales management. The strength of the FDI Medical network allows us to provide manufacturers with highly responsive local customer service supported by common protocols, programs and systems across the country. This dedication to high-quality customer relationships has been a key component in the ability of FDI Medical to successfully establish and maintain market share for the manufacturers we represent. FDI Medical, with its national network of distributors with specialized knowledge and marketing experience, is playing a vital role in this rapidly changing health care industry.
American Medical Diagnostics, Inc. (AMEDx) is a premier clinical pathology consultation service that provides laboratories and practicing physicians with timely, accurate, and up-to-date patient evaluations. Medical error is the 8th leading cause of death in the United States. In fact, half of the most common types of medical errors are related to misunderstood and mishandled lab results. AMEDx was created in response to the growing need for accurate and timely interpretation of laboratory data. Our service reduces medical errors, minimizes costs, and improves quality patient care by making lab results perfectly clear to the busiest of clinicians. AMEDx reduces the risk that clinicians will misinterpret laboratory data, and creates a revenue stream that supports your clinical laboratory experts! AMEDx provides in-lab productivity software (DxAuthor®) that enables cost-effective, clinically relevant interpretations that make a difference in patient care, save clinician's time, and leverage existing laboratory expertise into greater profitability. How does AMEDx work? Laboratory data are sent from the laboratory information system (LIS) through our secure internet connection. The laboratory's in house pathologists interpret the data or can automatically send results to world-class clinical experts for a consulting interpretation. The referring physician receives suggestions for interpretation of results, along with suggestions and commentary on areas of clinical significance. If the case is forwarded for interpretation, the consolidated consultative report is returned within two business days. No special phone calls. No lost time looking for a second opinion. Just quick, accurate, and reliable results analysis delivered directly to you.
http://www.siennacapital.com.au
Sienna Capital Ltd is a biotechnology company with a focus on using world-class research to develop and commercialise biosensing technologies. Sienna values its strong working relationship with the scientific and administrative team at the Ludwig Institute for Cancer Research (LICR) whose distinctive passion and dedication to bringing cancer under control is highly regarded around the world. Sienna is currently developing two biosensors. These are detection systems for the purpose of assessing disease treatment and efficacy of drug development, surveillance of disease progression and early detection of cancer. Sienna was formed in 2002 as an Australian public unlisted company. Sienna Cancer Diagnostics Pty Ltd is soley owned by Sienna Capital Ltd.
ISCHEM Corporation (ISCHEM) is a medical company that provides proprietary diagnostic, prognostic, and therapeutic products for the "vulnerable" person in the heart disease and stroke market place. ISCHEM has three initial cost-saving products under development that non-invasively identify and for the first time manage an asymptomatic individual's "vulnerability" to heart attack and stroke. ISCHEM's robust patented platform technology can also be applied to other major medical problems including heart failure, cancer, and Alzheimer's disease. These initial products are made by applying proprietary breakthrough data-analytic and statistical methods (e.g., neural network technologies and statistical artifact detection) to outcome data from landmark studies with extensive databases of medical histories.
http://www.cosmosbiomedical.com
Cosmos Biomedical Ltd is a modern medical diagnostics distributor founded on the utopian ideal of high quality plus customer satisfaction and support. Many years of knowledge, experience and professionalism culminate to provide the cornerstone of this company. The company charter emphasises the need to continually extend the boundaries of diagnostic science innovation to help promote good health and welfare in the community. The company stands by its belief that "prevention is better than cure" and will continually strive towards this goal. This will be achieved by continual investment into important medical research, to yield new and improved technology, leading to greater knowledge and understanding of disease pathogenesis. Cosmos Biomedical is a dynamic entity offering unique, CE Marked, niche market products, and is strongly committed to alleviate the suffering caused by infectious diseases, ultimately improving and saving lives. The Latest section will carry news and information from Cosmos Biomedical as well as any Special Offers available.
We have always believed that the patient deserves the best of care and the most responsive test result possible. Quality and availability has been a trademark of our organization. Our laboratories are well structured and organized to provide full support to any physician office, employer, or hospital realizing the value of local service and quality results. The DSI test menu is the largest in South Florida and, with few exceptions, in the state offering test results in Chemistry, Hematology, Coagulation, Microbiology, Virology, Molecular Medicine, and Toxicology. DSI Laboratories, Inc. is a wholly owned for profit subsidiary of NCH Healthcare System. It was formed in 1984 to provide laboratory services to the NCH Healthcare hospitals as well as physicians in their private practices in Collier County. Today, DSI Laboratories has grown to be a nationally recognized regional esoteric testing reference laboratory. We service clients throughout southwest Florida, marketing Clinical Laboratory services in Collier, Lee, Charlotte, and Sarasota counties and Toxicology services throughout the State. The DSI Regional Reference /Core Laboratory is located at Gateway in Fort Myers (Lee County) in a state of the art facility close to the Interstate and directly north of the Southwest Florida International Airport. This laboratory provides testing support to the hospitals and all testing to our physician clients. In addition to the Gateway Reference/ Core Laboratory in Fort Myers, DSI operates the Naples Community Hospital Laboratory, the North Collier Hospital Laboratory, and the Bonita Community Center Laboratory. Our 20 Patient Service Centers located throughout the Southwest Florida area offer professional and courteous service collecting blood samples and urine drug screens. DSI is certified by all major inspecting agencies and is one of only two SAMSHA certified laboratories for drug screening in Florida. We provide outstanding Information Technology including paperless order entry and reporting capabilities.
MediSys Corporation provides medical technology solutions to physicians in the internal medicine, family practice and general practice markets by offering innovative practice enhancement tools in the form of unique systems or modules. These easily integrated cost-effective modules enable doctors to provide superior medicine while significantly improving revenues and profits by leveraging their existing practice infrastructure. Each of these systems is also a practice enhancement/revenue enhancement tool for the financially distressed Primary Care Physician (PCP). Company research has uncovered several trends in PCP practice profitability. Increased operating costs and diminished reimbursement have lead to a financial crisis for these physicians. If these trends continue, and there is no reason to believe that they won't, the average PCP in the US will soon be earning less then $84,000 per year. The graph below demonstrates the trend of the eroding practice income for the PCP. The MediSys mission is to provide medical facilities with practice enhancement tools along with the training, support and marketing to properly implement them.
Synermed International Inc. is a development based diagnostic biochemistry company, established in 1989. Since that time, the Indianapolis, Indiana headquartered Company has invested millions of dollars in research toward the development of a new generation of diagnostic reagents and instruments. Synermed® has developed two reagent technologies which are unique in the diagnostic biochemistry world.
http://www.globaldiagnostics.co.uk
We are a leading provider of healthcare diagnostic services. Using a network of private clinics and the latest web-based imaging technologies we provide referrers (which can be Consultants, General Practitioners, Sports Medicine Physicians, Physiotherapists, Osteopaths or Chiropractors for example)with rapid access to scanning and reporting services. Our service is built upon our web-based IM&T (Information Management & Technology) backbone. Digital images from scanning systems such as MRI (magnetic resonance imaging), Ultrasound or X-ray instruments are transmitted, via a secure-web to a global network of expert radiologists. The radiologists then carry out a clinical diagnosis on-line and return a report, via the same secure web, back to the referring clinician in days or even hours. It's as simple as that - fast, accurate and highly secure! Meet the Global Diagnostics team below: Our Team Dr Johnny Walker
HEMONIX INC., located in Beaverton, Oregon, is a development stage medical diagnostics company founded by Charles L. Davis in 1996. Mr. Davis, one of the founders of Protocol Systems and its Vice President of Engineering, formed HEMONIX for the purpose of introducing a line of non-invasive cardiovascular monitoring technologies for the health care industry. With veteran management and a record of successful developments in patient monitoring technology, HEMONIX seeks to dominate the cardiovascular monitoring markets through superior technologies and strategic marketing alliances. Develop, produce, and distribute effective and comprehensive non-invasive monitoring instruments that dramatically improve the quality of health care delivery, while reducing its overall cost.
PrognostiX, Inc. was founded in 2004 based on novel biomarker technologies developed at the Cleveland Clinic (CC). The Company is involved in the discovery, development, and commercialization of proprietary molecular biomarkers that aid in the diagnosis and treatment of disease. The Company headquarters and laboratories are located on the CC campus in Cleveland, Ohio.
Since inception, Prolume has had a single mission, to make very small protein molecular light bulbs called NanoLights. To sell our NanoLights into several markets, ranging from drug discovery to consumer products. Since our founding in 1996, we have collected a large number of luminous coastal and deep-water marine animals. The DNA found within these animals was converted into genetic libraries, and the collection forms an extensive gene bank of rare and exotic genetic species. From our gene bank, we were able to clone six new NanoLight genes. These genes contain the DNA that encodes the NanoLight protein. Proteins that can be formed within a cell, are molecular flashlights, and change the color of light from blue to green. Our gene bank comes from animals that have been surviving in the oceans for hundreds of millions of years. The potential value of our gene bank is enormous. These animals make a large number of potentially valuable compounds. Many of these compounds have yet to be identified. Examples of new substances that could be found may include new digestive enzymes, new pharmaceuticals, and potentially new antibiotics. Presently we do not have the resources to utilize our gene bank for anything other than searching for new NanoLights. The value frozen within our gene bank may become apparent as more discovery is made upon DNA in general. We think that our gene bank contains elements that would be useful in the future. The gene bank will have more value once we make libraries of compounds that could be used in the search for new drugs. We have filed for patent protection upon six of our recently discovered NanoLight genes. We have recently begun licensing these genes to pharmaceutical and drug screening companies as aids to rapid screening. As an example of their utility: engineering the NanoLight DNA within a particular cell, can inform the pharmaceutical company that a potential new drug has been identified. This identification occurs rapidly because of light being on or off. Pharmaceutical companies no longer have to perform complicated chemical tests to see if their new drug candidate is active. This is the basis for high throughput drug screening using fluorescent or light emitting genes as reporting tools. Since very little information was known about our NanoLight genes, (we lacked the funds to experiment and market them commercially), revenue from NanoLight licensing was only $77,000.00 last year. However by January of this year, Rigel, Cellomics, and Roche Biosciences, have entered into research licenses with Prolume. The word is out about the high quality of our NanoLights. By word of mouth alone, we are currently negotiating with six other companies that are evaluating our NanoLight genes for potential licensing. Successful completion of these licenses could raise revenues to $350,000.00 or more per year. These revenues are annual license fees and minimum royalties with little further costs (only patent expenses) to Prolume. Revenues from sales of our NanoFuel products, (this is the light storage chemical used to turn on the NanoLight), are up; from $34,000.00 in 1998 to $130,000.00 in 2000. We are expanding this market by promoting research upon a new kind of biosensor utilizing two NanoLights linked together. We think that this new technology has broad application in protein-protein interaction, and will increase our understanding of how proteins work within cells. We feel that this market will expand in the future and increase sales and licenses for both product lines. Despite a complete sell out of 1,200 units of our New Years 2000 test market product the "Millennium Blaster" squirt guns, toy and consumer product revenue is lower than expected. This is primarily due to the fact that we have been working on upscaling our capacity for protein production and purification, which is necessary to produce enough toys for large orders. We also need to improve the product's play value and manufacture NanoLights at price points, that would interest the large chain stores. The chain stores want to see these products at a $1.95 retail price point, which translates to $1.05 wholesale price. The consumer markets are extremely large and any single order would double or triple Prolume's annual revenues. We have not solved the large-scale economic production of NanoLights yet. Considerably more research to genetically engineer appropriate yeasts or food grade bacteria to make NanoLights at 1-2 grams of NanoLights per liter of fermentation is required. This is easier said than done, since we have only one molecular biologist and only three employees. To avoid undue delay we have started this development by purchasing contract research with companies having more expertise in this field. We anticipate spending approximately $150,000.00 in the upcoming year to engineer NanoLight production and will be fortunate if we are successful on one or two of our genes. Success could mean entry into Wal-Mart, Target, and K-Mart with significant orders. Since NanoLights are our core technology and competence, we cannot allow ourselves to fall behind in discovery of new brighter and better NanoLights. We need to work on making different colors and improve the gene products of our existing NanoLights. If we had a range of colors, our licensing revenues could increase by five fold, because the large drug companies currently pay in the range of $500,000.00 to $1 Million for a set of 5-10 colors. There are currently few colors available. We have recently hired Dr. Shrikanth Hegde from St. Jude's Hospital to perform the molecular evolution that could improve our genes and to head our molecular biology research. In 1999, our scientists Dr. Ballou and Dr. Szent-Gyorgi obtained a small business incentive grant in the amount of $298,000.00 from the National Institute of Health. This grant was awarded upon Prolume's successful discovery of new NanoLight genes. This grant supports research to determine if two NanoLights placed together can be used to sense a chemical change by alteration in the displayed light color. While energy and time spent upon scientific research has delayed the production of NanoLights for consumer products, it remains in the heart of what our scientists really wanted to pursue. This area of research is very exciting and several drug companies are pursuing this independently and are speaking to us about collaborative research. [We screened our gene bank for NanoLights ideally suited to this area of research.] Success in this endeavor could expand our profitable NanoFuel market, which remains at very high profit mark-up but still too low in volume for multimillion-dollar sales. More good news came last year when three of our patents were allowed. Our Tumor Imaging, portions of the BioChip, and NanoLight Gene patents were allowed and are awaiting final publication. This could add potential new revenues this year since some companies are already looking at the technology. They are considering obtaining material transfers to study these potential future technologies as described in our utility patents.
CANAMET is a Canadian ISO13485: 2003 registered company that researches and develops non-invasive, medical diagnostic systems. CANAMET's products are targeted for use in hospitals, family clinics, ambulances, cardiologists and medical practitioner's offices. These systems are highly affordable and extremely accurate in environments that normally would make reliable measurement difficult or impossible. Established in June 2003, CANAMET has a team with a proven track record of successfully developing and achieving regulatory clearance for medical technologies that has worked together since 1997 at the Canadian Department of National Defense Laboratory, Defense R&D Canada (DRDC) Toronto.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory